Improving the Medication Management of Patients With Attention-Deficit Hyperactivity Disorder
| Status: | Withdrawn |
|---|---|
| Conditions: | Neurology, Psychiatric |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 5 - 12 |
| Updated: | 7/15/2018 |
| Start Date: | January 2013 |
| End Date: | August 2014 |
The specific aim of this cluster-randomized (site) comparative effectiveness research study
is to determine whether children who are (1) 5-12 years of age, (2) cared for in ePROS
practices or clinics using an electronic health record (EHR), (3) have attention-deficit
hyperactivity disorder (ADHD), and (4) are to receive treatment with stimulant medication for
the first time in these practices, have superior clinical outcomes if their clinicians have
access to an EHR-guided clinical decision support system (intervention group) than if their
clinicians have no such access (control group).
is to determine whether children who are (1) 5-12 years of age, (2) cared for in ePROS
practices or clinics using an electronic health record (EHR), (3) have attention-deficit
hyperactivity disorder (ADHD), and (4) are to receive treatment with stimulant medication for
the first time in these practices, have superior clinical outcomes if their clinicians have
access to an EHR-guided clinical decision support system (intervention group) than if their
clinicians have no such access (control group).
In this cluster (site)-randomized trial of clinical decision support for ADHD medication
titration, clinicians caring for children with ADHD whose families are initiating stimulant
medication at that practice will be followed.
Two groups will be compared; an intervention group, which will receive the intervention—the
clinical decision support (CDS)--, and a control group, who will not receive CDS. Over a
6-month period, the CDS will support guideline-based medication titration to achieve optimal
symptom control with minimal side effects. The study will track the care delivered to
affected children by the practitioners and will assess the endpoints of symptom reduction and
side effects. There will also be a sub-study within the larger study which will give the team
a better understanding about the pros and cons of consenting parents over the phone.
titration, clinicians caring for children with ADHD whose families are initiating stimulant
medication at that practice will be followed.
Two groups will be compared; an intervention group, which will receive the intervention—the
clinical decision support (CDS)--, and a control group, who will not receive CDS. Over a
6-month period, the CDS will support guideline-based medication titration to achieve optimal
symptom control with minimal side effects. The study will track the care delivered to
affected children by the practitioners and will assess the endpoints of symptom reduction and
side effects. There will also be a sub-study within the larger study which will give the team
a better understanding about the pros and cons of consenting parents over the phone.
Practice Eligibility Criteria
- Willing to offer the possibility of study enrollment to their patients who have ADHD
- Willing to use the Vanderbilt Assessment Rating Scale to assess and potentially, to
monitor ADHD for study subjects
- Utilize Integrated Health Connect as a means to collect the Vanderbilt Assessment
Rating Scale
- Use point-of-care reports for subjects enrolled in the study.
Patient Eligibility Criteria
- The child must be between the ages of 5-12 years old
- The child must be starting stimulant medication for the first time
- Parent must be able to speak and read English
- The child must not be diagnosed with a current manic episode, a psychotic disorder, or
a pervasive developmental disorder (e.g. autism, Asperger's, Rett's disorder)
- The child must not have reported suicidality or have conduct disorder, per
parent/guardian report
We found this trial at
1
site
Click here to add this to my saved trials
